» Articles » PMID: 22172723

IL-10 Elicits IFNγ-dependent Tumor Immune Surveillance

Abstract

Tumor immune surveillance and cancer immunotherapies are thought to depend on the intratumoral infiltration of activated CD8(+) T cells. Intratumoral CD8(+) T cells are rare and lack activity. IL-10 is thought to contribute to the underlying immune suppressive microenvironment. Defying those expectations we demonstrate that IL-10 induces several essential mechanisms for effective antitumor immune surveillance: infiltration and activation of intratumoral tumor-specific cytotoxic CD8(+) T cells, expression of the Th1 cytokine interferon-γ (IFNγ) and granzymes in CD8(+) T cells, and intratumoral antigen presentation molecules. Consequently, tumor immune surveillance is weakened in mice deficient for IL-10 whereas transgenic overexpression of IL-10 protects mice from carcinogenesis. Treatment with pegylated IL-10 restores tumor-specific intratumoral CD8(+) T cell function and controls tumor growth.

Citing Articles

Preconditioning with Wound Fluid Enhances Immunosuppressive Properties of Mesenchymal Stromal Cells In Vitro.

Moratin H, Mache I, Goncalves M, Ehret Kasemo T, Stoth M, Meyer T Int J Mol Sci. 2025; 26(1.

PMID: 39796154 PMC: 11719632. DOI: 10.3390/ijms26010293.


Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer.

Liu X, Xi X, Xu S, Chu H, Hu P, Li D Front Immunol. 2024; 15:1507501.

PMID: 39726592 PMC: 11669709. DOI: 10.3389/fimmu.2024.1507501.


Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up.

Duan H, He Z, Chen Z, Chen Y, Hu W, Sai K BMC Immunol. 2024; 25(1):83.

PMID: 39707189 PMC: 11662448. DOI: 10.1186/s12865-024-00676-2.


Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways.

Zhang Y, Guo N, Zhu H, Liu M, Hao J, Wang S Theranostics. 2024; 14(18):7054-7071.

PMID: 39629133 PMC: 11610140. DOI: 10.7150/thno.102037.


Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy.

Newman M Front Immunol. 2024; 15:1462221.

PMID: 39606250 PMC: 11599860. DOI: 10.3389/fimmu.2024.1462221.